Milademetan is an oral agent that targets the MDM2*-p53 interaction, a key mediator of many malignancies. Milademetan is currently in clinical development for patients with MDM2-dependent, TP53 wildtype cancers.
Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights
December 13, 2023 6:12 PM
NEWARK, Calif., December 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (Nasdaq: RAIN) (“Rain”), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. (“Pathos”) will acquire Rain for $1.16 in cash per share plus a non-tradeable contingent value right (a “CVR”) for potential cash payments of up to approximately $0.17 per share.
Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
November 9, 2023 4:01 PM
NEWARK, Calif., November 9, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), today reported financial results for the third quarter ended September 30, 2023, along with an update on the Company’s key developments and business operations.
Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
October 16, 2023 8:00 AM
NEWARK, Calif., October 16, 2023 – Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net proceeds payable from any license or disposition of Rain’s programs.
